GF CSI Innovative Drugs Industry ETF (515120) rises 5.18%, with a share increase of 431 million units over the past 2 weeks

NewTimeSpace (newtimespace.com) News, as of 10:58 on July 15, 2026, GF Innovative Drug ETF (515120) rose 5.18%, with the latest price at 0.69 yuan. Over a longer time frame, as of July 14, 2026, the ETF accumulated a gain of 5.63% over the past week.

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 9% and a trading volume of 1.145 billion yuan. Over a longer time frame, as of July 14, the ETF's average daily trading volume over the past week reached 943 million yuan, ranking in the top 2 among comparable funds.

In terms of scale, the latest scale of GF Innovative Drug ETF reached 12.226 billion yuan, hitting a one-year high and ranking 2/7 among comparable funds. (Data source: Wind)

In terms of shares, GF Innovative Drug ETF experienced a significant increase of 431 million units in share count over the past two weeks, with the new share increase ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for GF Innovative Drug ETF was 128 million yuan. Over a longer time frame, within the past five trading days, there were four days of net inflow, attracting a total of 43.7251 million yuan, with an average daily net inflow of 8.7450 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The net margin financing purchase amount of GF Innovative Drug ETF on the previous trading day reached 2.3391 million yuan, with the latest margin financing balance standing at 409 million yuan. (Data source: Wind)

As of July 14, the net value of GF Innovative Drug ETF rose by 41.12% over the past two years. From the perspective of return capability, as of July 14, 2026, since its inception, the ETF achieved a highest single-month return of 23.00%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 32.68%, and an average return of 5.48% in up months. As of July 14, 2026, the ETF's annualized excess return over its benchmark for the past three months was 3.74%.

In terms of drawdown, as of July 14, 2026, GF Innovative Drug ETF recorded a drawdown of 0.14% relative to its benchmark over the past six months, reflecting lower drawdown risk among comparable funds.

In terms of fees, GF Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of July 14, 2026, the two-year tracking error of GF Innovative Drug ETF was 0.026%, achieving the highest tracking accuracy among comparable funds.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.